Soligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.
Follow SNGX
Soligenix Inc. (SNGX) Altman Z-score
Soligenix Inc.'s Altman Z-score for fiscal 2024 is −38.90, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −38.90 | (5.04) |
| FY2023 | −33.86 | (9.58) |
| FY2022 | −24.28 | (13.87) |
| FY2021 | −10.41 | 4.04 |
| FY2020 | −14.45 | 18.18 |
| FY2019 | −32.63 | (10.42) |
| FY2018 | −22.21 | (0.41) |
| FY2017 | −21.80 | (3.00) |
| FY2016 | −18.80 | 8.67 |
| FY2015 | −27.47 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.44 | — | 0.53 | |
| Retained earnings / total assets | (26.09) | — | −36.53 | |
| EBIT / total assets | (1.05) | — | −3.47 | |
| Market value of equity / total liabilities | 0.92 | — | 0.55 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −38.90 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −88.34 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KPTI Karyopharm Therapeutics Inc. compare | −23.9× |
| APRE Aprea Therapeutics, Inc. compare | −30.1× |
| SNGX Soligenix Inc. | −38.9× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | — |
| CNSP CNS Pharmaceuticals, Inc. compare | — |
| MBRX Moleculin Biotech, Inc. compare | — |
| CALC CalciMedica Inc. compare | — |
| XTLB XTL Biopharmaceuticals Ltd. compare | — |
| CURX Curanex Pharmaceuticals Inc compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets